Andrew W Silagy1, Roy Mano2, Kyle A Blum2, Renzo G DiNatale2, Julian Marcon2, Satish K Tickoo3, Eduard Reznik4, Jonathan A Coleman2, Paul Russo2, A Ari Hakimi5. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia. 2. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Genitourinary Oncology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: hakimia@mskcc.org.
Abstract
OBJECTIVE: To assess which patients respond best following cytoreductive nephrectomy for renal cell carcinoma (RCC) with sarcomatoid dedifferentiation (sRCC) and whether outcomes are improving over time. METHODS: We identified 562 patients with metastatic RCC treated between 1989 and 2018 with cytoreductive nephrectomy. We reviewed baseline clinical and pathologic characteristics, including the presence of sRCC, and metastatic sites at time of nephrectomy. The primary study endpoint was overall survival (OS). Univariate and multivariate Cox-regression analyses were used to identify significant predictors of OS. RESULTS: The study cohort had 192 sRCC patients, with a median age of 59 years. Frequently involved metastatic locations were lung (n = 115), retroperitoneal nodes (n = 63), and axial skeleton (n = 43). Lung metastasis were more prevalent in clear cell histology (P = .0017) whereas nodal involvement was associated with nonclear cell subtypes (P = .0064). Median follow-up was 14 months. Estimated 2- and 5-year OS were 34.1% and 14.8%, respectively. On multivariate analysis, metastases to the liver (HR = 1.64; 95% CI 1.02-2.63; P = .04), lung (HR = 1.50; 95% CI 1.05-2.14; P = .03), retroperitoneal nodes (HR = 1.52; 95% CI 1.03-2.25; P = 0.04) and nonclear cell histology (HR = 1.61; 95% CI 1.10-2.35; P = .01) were associated with worse OS in the sRCC cohort. CONCLUSION: OS after cytoreductive nephrectomy for sRCC and non-sRCC is improving over time. In patients with sRCC, presentations with unifocal metastasis not involving the liver or lung, clear cell histology and node negative disease have better outcomes following cytoreductive nephrectomy and may yield greater benefit from the procedure.
OBJECTIVE: To assess which patients respond best following cytoreductive nephrectomy for renal cell carcinoma (RCC) with sarcomatoid dedifferentiation (sRCC) and whether outcomes are improving over time. METHODS: We identified 562 patients with metastatic RCC treated between 1989 and 2018 with cytoreductive nephrectomy. We reviewed baseline clinical and pathologic characteristics, including the presence of sRCC, and metastatic sites at time of nephrectomy. The primary study endpoint was overall survival (OS). Univariate and multivariate Cox-regression analyses were used to identify significant predictors of OS. RESULTS: The study cohort had 192 sRCC patients, with a median age of 59 years. Frequently involved metastatic locations were lung (n = 115), retroperitoneal nodes (n = 63), and axial skeleton (n = 43). Lung metastasis were more prevalent in clear cell histology (P = .0017) whereas nodal involvement was associated with nonclear cell subtypes (P = .0064). Median follow-up was 14 months. Estimated 2- and 5-year OS were 34.1% and 14.8%, respectively. On multivariate analysis, metastases to the liver (HR = 1.64; 95% CI 1.02-2.63; P = .04), lung (HR = 1.50; 95% CI 1.05-2.14; P = .03), retroperitoneal nodes (HR = 1.52; 95% CI 1.03-2.25; P = 0.04) and nonclear cell histology (HR = 1.61; 95% CI 1.10-2.35; P = .01) were associated with worse OS in the sRCC cohort. CONCLUSION: OS after cytoreductive nephrectomy for sRCC and non-sRCC is improving over time. In patients with sRCC, presentations with unifocal metastasis not involving the liver or lung, clear cell histology and node negative disease have better outcomes following cytoreductive nephrectomy and may yield greater benefit from the procedure.
Authors: Anthony T Corcoran; Samuel D Kaffenberger; Peter E Clark; John Walton; Elizabeth Handorf; Zack Piotrowski; Jeffery J Tomaszewski; Serge Ginzburg; Reza Mehrazin; Elizabeth Plimack; David Y T Chen; Marc C Smaldone; Robert G Uzzo; Todd M Morgan; Alexander Kutikov Journal: BJU Int Date: 2014-12-15 Impact factor: 5.588
Authors: Christos E Kyriakopoulos; Namita Chittoria; Toni K Choueiri; Nils Kroeger; Jae-Lyun Lee; Sandy Srinivas; Jennifer J Knox; Georg A Bjarnason; Scott D Ernst; Lori A Wood; Ulka N Vaishampayan; Neeraj Agarwal; Sumanta K Pal; Ravindran Kanesvaran; Sun-Young Rha; Takeshi Yuasa; Frede Donskov; Scott A North; Daniel Y Heng; Brian I Rini Journal: Clin Genitourin Cancer Date: 2014-09-23 Impact factor: 2.872
Authors: Stephen H Culp; Nizar M Tannir; E Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F Matin; Christopher G Wood Journal: Cancer Date: 2010-07-15 Impact factor: 6.860
Authors: Brian Shuch; Gennady Bratslavsky; Joanna Shih; Srinivas Vourganti; David Finley; Brandon Castor; Eric Treat; W Marston Linehan; Allan J Pantuck; Jonathan W Said; Arie S Belldegrun Journal: BJU Int Date: 2012-01-05 Impact factor: 5.588
Authors: Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Arun Z Thomas; Mehrad Adibi; Rebecca S Slack; Leonardo D Borregales; Megan M Merrill; Pheroze Tamboli; Kanishka Sircar; Eric Jonasch; Nizar M Tannir; Surena F Matin; Christopher G Wood; Jose A Karam Journal: J Urol Date: 2016-03-29 Impact factor: 7.450
Authors: Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Andrew W Silagy; Ritesh R Kotecha; Stanley Weng; Arturo Holmes; Nirmish Singla; Roy Mano; Kyrollis Attalla; Kate L Weiss; Renzo G DiNatale; Sujata Patil; Jonathan A Coleman; Robert J Motzer; Paul Russo; Martin H Voss; A Ari Hakimi Journal: Cancer Date: 2021-07-19 Impact factor: 6.860